Home › Cancer types › Breast Cancer

Just diagnosed with breast cancer?

By the Cancer Clues team · Last updated 1 November 2026 · How we grade treatments

The honest numbers

• About 322,000 US diagnoses expected in 2026 — the most common cancer in women; roughly 1 woman in 8 over a lifetime; median age 64 [1].
• Five-year relative survival (2016–2022 diagnoses): 92% overall — 100% localized (64% of diagnoses), 88% regional, 34% after distant spread [1]. Metastatic disease is treatable, often for years, though usually not curable — honesty requires both halves of that sentence.
• These are group numbers; your subtype, stage and genomics set your actual range.

What's actually proven

• Subtype decides treatment. Hormone-receptor-positive cancers get years of endocrine (anti-hormone) therapy, often with CDK4/6-inhibitor pills; HER2-positive cancers get targeted antibodies; triple-negative cancers lean on chemo, now often with immunotherapy [2][3].
• Lumpectomy + radiation equals mastectomy for survival — proven over 20 years of follow-up in randomized trials. Bigger surgery is not safer surgery for most women [4].
• The chemo question often has a test: for the most common subtype (hormone-positive, HER2-negative, node-negative), a genomic score from your tumor (Oncotype DX) identifies most women — especially over 50 — who can safely skip chemotherapy [5].
• Removing the healthy breast “to be safe” adds no survival benefit for average-risk women; surgical societies actively discourage it. (Different story for BRCA carriers — ask about genetic testing.) [6]

Depth by stage and subtype: the National Cancer Institute's patient hub [2] and the NCCN patient guideline [3].

What people ask about (from our graded library)

• Fasting around chemo — the biggest trial (DIRECT) was in breast cancer: cure rates and severe side effects unchanged, some secondary signals, only 20% managed the diet every cycle. Graded Unknown; never if you're losing weight.
• Turmeric / curcumin — a human study showed it lowers the active form of tamoxifen — a genuinely important interaction if you're on endocrine therapy. The one positive trial used an IV formulation you can't buy.
• Cannabis & CBD — fine to discuss for symptoms, but if you're on immunotherapy (some triple-negative treatment), read the caution about blunted response.
• Ivermectin — the one human cancer trial happens to be in triple-negative breast cancer: safety-phase only, no efficacy results yet. Graded Unknown.

Does the hospital matter?

Less dramatically than for pancreatic or rectal surgery — guideline-quality breast care is widely available — but two things measurably help: being treated by a multidisciplinary team (an observational study found 18% lower breast-cancer mortality after team care was introduced [7]), and treatment at accredited breast centers, which follow quality processes more reliably [8]. The practical version: you don't need to fly anywhere famous for most breast cancer — you need your case reviewed by a team, your subtype tested fully, and a surgeon and oncologist who do this all day. A remote second opinion settles nerves and occasionally changes plans — we arrange those.

What's new (and real)

• “HER2-low” now matters: a smart drug (trastuzumab deruxtecan) was approved in January 2025 for metastatic cancers with even faint HER2 — a group told for decades they were “HER2-negative”. If you're metastatic, ask whether your tumor is HER2-low [9].
• Recurrence-prevention pills broadened: ribociclib (a CDK4/6 inhibitor) was approved in 2024 alongside endocrine therapy for higher-risk early hormone-positive disease [10].
• Screening now starts at 40: the US task force moved to recommending mammograms every two years from age 40 (2024). Tell your sisters and daughters [11].
• Vaccines: early-stage trials only (a preventive triple-negative vaccine finished phase 1 in late 2025 — immune responses, no efficacy data yet). Hopeful, not available [12].

Questions for your oncologist (bring this list)

1. What exactly is my subtype (ER/PR, HER2 — including HER2-low — and grade), and what does each result change?
2. Am I a candidate for lumpectomy plus radiation instead of mastectomy?
3. Does a genomic score (Oncotype or similar) apply to me — could it let me skip chemo safely?
4. Should I have genetic (BRCA) testing, and would it change surgery?
5. Will my case be reviewed by a multidisciplinary team — and which trials fit me?

Common questions